Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. 1997

N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
Abteilung Klinische Chemie, Zentrum Innere Medizin, Georg August Universität Göttingen, Germany.

In a prospective study over 6 months, the relationship between serum lipid parameters and CsA whole blood trough concentrations was investigated in 39 renal transplant recipients receiving a triple immunosuppressive therapy with cyclosporin (CsA), azathioprine and prednisone. CsA trough concentrations were measured with a selective monoclonal immunoassay (Abbott TDx). Six months after transplantation, significant positive correlations were observed between the CsA trough concentration and serum concentrations of triglycerides (r = 0.448, p < 0.01), total cholesterol (r = 0.360, p < 0.05), and apoB (r = 0.418, p < 0.01). After exclusion of patients with over hypertriglyceridemia (> 400 mg/dl), however, the associations were no longer significant. HDL-cholesterol (HDL-C) and apo AI concentrations showed significant inverse correlations with the CsA trough level (HDL-C: r = -0.427, p < 0.01; apoAI: r = -0.350, p < 0.05); the correlations with the CsA trough level were still significant (HDL-C: r = -0.379, p < 0.05; apoAI: r = -0.354, p < 0.05) after exclusion of patients with triglyceride levels of > 400 mg/dl. As a result of these divergent effects on the plasma lipids and lipoproteins, there was a strong positive association (r = 0.633, p < 0.001) between the CsA trough concentration and the total cholesterol/HDL-C ratio. Consequently, elevated total cholesterol/HDL-C ratios that represent an increased atherogenic risk tended to be associated with higher CsA trough levels. In monitoring CsA therapy of renal transplant recipients on maintenance immunosuppressive therapy, it may well be advisable to adjust CsA dosages to obtain CsA trough levels within the lower therapeutic range for patients with an unfavorably high TC/HDL-C ratio.

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001053 Apolipoproteins Protein components on the surface of LIPOPROTEINS. They form a layer surrounding the hydrophobic lipid core. There are several classes of apolipoproteins with each playing a different role in lipid transport and LIPID METABOLISM. These proteins are synthesized mainly in the LIVER and the INTESTINES. Apolipoprotein
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug

Related Publications

N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
February 2000, Pediatric transplantation,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
May 2016, Medical mycology,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
August 2003, Journal of clinical gastroenterology,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
September 2018, Clinical pharmacokinetics,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
January 1983, Progress in clinical and biological research,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
August 2016, Medical mycology,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
March 2012, Clinical pharmacokinetics,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
December 1995, Therapeutic drug monitoring,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
January 2000, The Hopkins HIV report : a bimonthly newsletter for healthcare providers,
N von Ahsen, and M Helmhold, and E Schütz, and T Eisenhauer, and V W Armstrong, and M Oellerich
July 2002, The British journal of dermatology,
Copied contents to your clipboard!